전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,399 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 195Status Approved
ADCCurated CoreFDAstaleRocheDM1 (maytansine derivative)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, Trastuzumab Emtansine)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 186Status Approved
ADCCurated CoreFDAstaleSeagenvedotin and the anti-HER2 t…Approved

brentuximab vedotin (Adcetris)

Hodgkin's Disease · Hodgkin Disease

#HodgkinDisease#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 180Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

evolocumab (Repatha, AMG-145)

Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH · PCSK9

#PCSK9#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 143Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

teclistamab-cqyv (Tecvayli, JNJ-64007957, teclistamab)

Relapsed or refractory multiple myeloma · BCMA × CD3

#BCMACD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 132Status Approved
AntibodyCurated CoreFDAstaleAbbVieApproved

risankizumab-rzaa (Skyrizi, BI 655066, risankizumab)

Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 110Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

lebrikizumab-lbkz (Ebglyss, LY3650150, lebrikizumab)

Moderate-to-severe atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 108Status Approved
AntibodyCurated CoreFDAstaleSanofiApproved

alirocumab (Praluent, REGN727, SAR236553)

Hyperlipidemia, ASCVD, HeFH · PCSK9

#PCSK9#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 103Status Approved
ADCCurated CoreFDAstaleRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA-approved#BioJungboMoa-pick+5
Trials 91Status Recruiting
AntibodyCurated CoreFDAstaleRocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAstaleJohnson & JohnsonApproved

guselkumab (Tremfya, CNTO 1959)

Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease · IL-23 p19

#IL-23p19#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 87Status Approved
ADCCurated CoreFDAstaleGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 78Status Discontinued
AntibodyCurated CoreFDAstaleNovartisApproved

inclisiran (Leqvio, KJX839, ALN-PCS)

Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) · PCSK9 (siRNA)

#PCSK9siRNA#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 72Status Approved
CGTCurated CoreFDAstaleKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 68Status Approved
AntibodyCurated CoreFDAstaleUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyCurated CoreFDAstaleGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

faricimab (Vabysmo, RG7716, faricimab-svoa)

Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion · Ang-2 / VEGF-A

#Ang-2VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 53Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd)

HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior thera… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
CGTCurated CoreFDAstaleNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved

2 / 120 pages

← PreviousNext →